Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -0.54%70 Gross Margin % is 42.65% as of Mar. 2026, which is 22% above its 10-year median of 34.91. GuruFocus rates NSE:BALAXI with a GF Score™ of 70/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks worse than 57.69% on this metric.
NSE:BALAXI's Gross Margin % is ranked worse than 57.69% of 943
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:BALAXI: 44.16
Balaxi Pharmaceuticals had a gross margin of 42.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Balaxi Pharmaceuticals was 12.10% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Balaxi Pharmaceuticals had a gross margin of 42.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Balaxi Pharmaceuticals Gross Margin % Related Terms
Balaxi Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Balaxi Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BALAXI vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Balaxi Pharmaceuticals (NSE:BALAXI) has a Gross Margin % of 42.65% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Balaxi Pharmaceuticals and its competitors. This is 22% above median its historical median of 34.91. Over the past decade, Balaxi Pharmaceuticals' Gross Margin % has ranged from 24.70 to 46.67. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #544 out of 943 companies in the Drug Manufacturers industry, placing it in the top 57.7%.
Is Balaxi Pharmaceuticals' Gross Margin % too high?
Balaxi Pharmaceuticals' current Gross Margin % of 42.65% is 22% above median its 10-year median of 34.91. Over the past 10 years, this metric has ranged from a low of 24.70 to a high of 46.67. The Drug Manufacturers industry median Gross Margin % is 48.54. Balaxi Pharmaceuticals' value of 42.65% is 12.1% below this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #544 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Balaxi Pharmaceuticals has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #544 out of 943 companies for Gross Margin %. This places Balaxi Pharmaceuticals in the lower half of its industry. The industry median Gross Margin % is 48.54. Balaxi Pharmaceuticals' value of 42.65% is 12.1% below this benchmark. Historically, Balaxi Pharmaceuticals' own Gross Margin % has ranged from 24.70 to 46.67 over the past decade. While the company's 10-year median is 34.91 vs. the industry median of 48.54, Balaxi Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current Gross Margin % of 42.65% is 12.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current Gross Margin % is 42.65%, which is 22% above median its own 10-year median of 34.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current Gross Margin % is 42.65%, which is 22% above median its 10-year median of 34.91 and 12.1% below the Drug Manufacturers industry median of 48.54. Balaxi Pharmaceuticals' overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current Gross Margin % is 42.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
Gross Margin %: 42.65% (22% above median its 10-year median of 34.91)
GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
Industry Position: 12.1% below the Drug Manufacturers median (#544 of 943)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
70GF Score
Get the complete analysis for NSE:BALAXI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
